Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Presentation and Diagnosis.
Fiche publication
Date publication
juin 2020
Journal
Hematology/oncology clinics of North America
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric, Pr GARNACHE-OTTOU Francine
Tous les auteurs :
Deconinck E, Petrella T, Garnache Ottou F
Lien Pubmed
Résumé
Clinical and biological presentation of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) is depicted to highlight criteria that might alert physicians. Diagnosis of BPDCN is still challenging and requires (1) immunophenotyping of blood or bone marrow aspiration using several markers (CD4, CD56, HLA-DR, myeloid and lymphoid lineage markers) and should include pDC markers such as CD123, cTCL1, CD303, and CD304, and/or (2) pathologic analysis of cutaneous lesions, also with immunohistochemistry using markers specific to BPDCN.
Mots clés
Anatomopathology, BPDCN, Clinical presentation, Diagnosis, Immunophenotyping, Morphologies
Référence
Hematol. Oncol. Clin. North Am.. 2020 Jun;34(3):491-500